Fundraising Fox
/Companies
Sign in

AmideBio

Boulder, US · Founded 2009 · Colorado LLC

Find your way into AmideBio

Sign up to see every warm intro you have to AmideBio

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the AmideBio team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

AmideBio discovers and designs peptide therapeutics for metabolic diseases, using in-silico design and its BioPure process to produce ultrapure peptides. It also sells manufactured peptides and offers custom synthesis services to the biopharmaceutical industry and research community, aiming to license drug candidates at or before the IND stage.

AI & Machine LearningBiotechDeep TechHealthtech

Founders & leadership

AmideBio was founded in 2009 by Michael H. B. Stowell.

MH
Michael H. B. StowellCSO, Founder and Board Member
MP
Mikhail PlamExecutive
PF
Pawel Fludzinski, PhDCEO, President and Board Member
PFPawel Fludzinski
Pawel FludzinskiCEO, President and Board Member
DW
Derek WatsonFractional CFO

Board

DB
David BarkerBoard director
VP
Vincent P. MihalikBoard director
RC
Ruel C. MercureBoard director
NU
Niles UtlautBoard director
DB
David BrunelBoard director
GA
Gregory AbbottBoard director

Reported raises · per SEC filings

Form D private placements

$1.8M disclosed across 4 rounds · 2013–2017

▶$763.5KraisedNov 2017 · 9 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Ruel C. MercureDirector
  • David BrunelDirector
  • Niles UtlautDirector
  • Gregory AbbottDirector
  • David BarkerDirector
  • Michael H.B. StowellExecutive Officer, Director
  • Mikhail PlamExecutive Officer, Director
  • Vincent P. MihalikDirector
Offering amount
$763.5K
Amount sold
$763.5K
First sale
Oct 2017
Incorporated
Limited Liability Company, Colorado
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$396KraisedApr 2017 · 9 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • David BarkerDirector
  • Michael H.B. StowellExecutive Officer, Director
  • Mikhail PlamExecutive Officer, Director
  • Ruel C. MercureDirector
  • Gregory AbbottDirector
  • Vincent P. MihalikDirector
  • David BrunelDirector
  • Niles UtlautDirector
Offering amount
$768K
Amount sold
$396K
First sale
Apr 2016
Incorporated
Limited Liability Company, Colorado
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$279.3KraisedJan 2015 · 5 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • David BarkerDirector
  • Vincent P. MihalikDirector
  • Michael H.B. StowellExecutive Officer, Director
  • Ruel C. MercureDirector
  • Mikhail PlamExecutive Officer, Director
  • Niles UtlautDirector
  • David BrunelDirector
  • Gregory AbbottDirector
Offering amount
$1.1M
Amount sold
$279.3K
First sale
Dec 2014
Incorporated
Limited Liability Company, Colorado
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$400KraisedMay 2014 · 4 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Mikhail PlamExecutive Officer, Director
  • Ruel C. MercureDirector
  • Michael H.B. StowellExecutive Officer, Director
  • Gregory AbbottDirector
  • David BarkerDirector
  • Vincent P. MihalikDirector
  • Niles UtlautDirector
Offering amount
$750K
Amount sold
$400K
First sale
Dec 2013
Incorporated
Limited Liability Company, Colorado, 2009
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 2

IQVIAIQVIA is a healthcare data and technology company that supports life sciences organizations in research, clinical development, and commercialization of medicines and medical solutions.
Aadi BioscienceAadi Bioscience develops therapies targeting mTOR-driven diseases using precision medicine and albumin-bound nanoparticle technology, applying genomic profiling to identify patients most likely to benefit from mTOR inhibition. It operates in the biotechnology and pharmaceutical sector.

Companies working in the same space as AmideBio.

Non-dilutive funding · 4 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase II2022$2.7M
National Institutes of Health (NIH)National Institutes of HealthPhase I2021$300K
National Institutes of Health (NIH)National Institutes of HealthPhase II2019$1.6M
National Institutes of Health (NIH)National Institutes of HealthPhase I2017$338.4K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

In the news

AmideBio Awarded Direct-to-Phase 2 SBIR Grant to Develop Dual Agonist Insulins for Treating Diabetics with Impaired Awareness of Hypoglycemia (IAH) | Amidebioamidebio.com · Sep 2024

Frequently asked questions

What does AmideBio do?
AmideBio discovers and designs peptide therapeutics for metabolic diseases, using in-silico design and its BioPure process to produce ultrapure peptides. It also sells manufactured peptides and offers custom synthesis services to the biopharmaceutical industry and research community, aiming to license drug candidates at or before the IND stage.
Who founded AmideBio?
AmideBio was founded by Michael H. B. Stowell in 2009.
How much funding has AmideBio raised?
AmideBio has disclosed $1.8M raised across 4 rounds.
Where is AmideBio headquartered?
AmideBio is headquartered in Boulder, US.